Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 16/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209792 | 0.92 | ADRB2 (0.39) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5212693 | 0.92 | ADRB2 (0.39) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5207305 | 0.90 | ADRB2 (0.33) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5943651 | 0.89 | ADRB2 (0.34) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5943664 | 0.89 | ADRB2 (0.39) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5943666 | 0.88 | ADRB2 (0.36) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5215049 | 0.88 | ADRB2 (0.36) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5943639 | 0.88 | ADRB2 (0.36) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5212239 | 0.87 | ADRB2 (0.35) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5212232 | 0.87 | ADRB2 (0.35) | ADRB3ADRB1ADRB2ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554264-B1 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205790-A1 | Medicinal arylethanolamine compounds | NAT1, AADAC, AHR | ADRB3 70/4885ADRB1 120/4885ADRB2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.